Nifedipine and Lazertinib: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Nifedipine
Lazertinib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased NIFEdipine exposure
Interaction Deep Dive
Concomitant use of NIFEdipine, a CYP3A4 substrate, with a CYP3A4 inhibitor may increase NIFEdipine exposure and increase hypotensive effects1. Coadministration of erythromycin (CYP3A inhibitor) with a calcium channel blocker (including NIFEdipine) was associated with significantly increased short-term risk of hospital admission within 7 days for hypotension or shock in a cohort study of geriatric patients 4. If coadministration is required, NIFEdipine dosage adjustment and monitoring may be necessary 32. Initiate NIFEdipine at the lowest dose available if given concomitantly with CYP3A4 inhibitors 32.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism of NIFEdipine
Literature reports
1 report — tap to read
a) Coadministration of macrolide antibiotics erythromycin or clarithromycin with a calcium channel blocker was associated with significantly increased short-term risk of hospital admission within 7 days for hypotension or shock ([OR, 5.8; 95% CI, 2.25 to 14.98] or [OR, 3.7; 95% CI, 2.26 to 6.06]) in a case-crossover cohort study of geriatric patients (N=7100); there was no significant risk associated with azithromycin. In a stratified analysis of dihydropyridine calcium channel blockers (amLODIPine, felodipine, NIFEdipine), the results remained significant for coadministration of erythromycin or clarithromycin. Calcium channel blocker treatment included dilTIAZem (40%), amLODIPine (29.6%), NIFEdipine (19.4%), verapamil (8%), or felodipine (3%). The findings suggest that erythromycin and clarithromycin potentiate calcium channel blockers (CYP3A4 substrates) by inhibiting CYP3A4; azithromycin does not inhibit CYP3A4 4.
Common questions
Can I take Nifedipine and Lazertinib together?
Increased NIFEdipine exposure Always confirm with your pharmacist or prescriber before making any change.
How serious is the Nifedipine and Lazertinib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Nifedipine or Lazertinib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (4)
- Product Information: ADALAT(R) XL(R) oral extended-release tablets, nifedipine oral extended-release tablets. Bayer Inc (per Health Canada), Mississauga, Ontario, Canada, 2016. DailyMed
- Product Information: NIFEDIPINE oral tablet, extended-release, nifedipine oral tablet, extended-release. Aurobindo Pharma Limited (per DailyMed), East Windsor, NJ, 2024. DailyMed
- Product Information: PROCARDIA XL(R) oral extended-release tablets, nifedipine oral extended-release tablets. Pfizer Labs (per Dailymed), New York, NY, 2023. DailyMed
- Wright AJ, Gomes T, Mamdani MM, et al: The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers. CMAJ 2011; 183(3):303-307. PubMed
Keep reading about Nifedipine
Keep reading about Lazertinib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist